Considering the results of our previous research that conjugated linoleic acid mixture-paclitaxel （CLA-mixture-PTX） possesses anti-tumor activity against melanoma and brain glioma, the purpose of this study was to i...Considering the results of our previous research that conjugated linoleic acid mixture-paclitaxel （CLA-mixture-PTX） possesses anti-tumor activity against melanoma and brain glioma, the purpose of this study was to investigate the potential anti-tumor efficacy of cis-9, trans- 1 1-conjugated linoleic acid-paclitaxel （c9, tl 1-CLA-PTX） and trans- 1 O, cis- 12-conjugated linoleic acid-paclitaxel （tl0, c12-CLA-PTX） on MCF-7 breast cancer cell line in vitro and in vivo. The in vitro cytotoxicity, apoptosis induction effect and cell cycle arresting effect of c9, t1 1-CLA-PTX and t10, c12-CLA-PTX were investigated. The in vitro cellular uptake of c9, tl 1-CLA-PTX and tl0, cl2-CLA-PTX in MCF-7 cells were also analyzed. Besides, the anti-tumor activity of c9, tl 1-CLA-PTX and tl0, cl2-CLA-PTX was evaluated in MCF-7 tumor bearing nude mice in vivo. The in vitro cytotoxicity results showed that the value of ICs0 of the tl 0, c l2-CLA-PTX is （0.17±0.02） μM, compared with that of （1.08±0.15） μM in CLA-mixture-PTX and （6.50±1.20） μM in c9, tl 1-CLA-PTX treatment group （P〈0.01）. Both tl0, cl2-CLA-PTX and c9, t l 1-CLA-PTX increased the percentage of total apoptotic cells compared with that of control （P〈0.01）. And the rank of apoptosis induction efficacy was t 10, c 12-CLA-PTX〉CLA-mixture-PTX〉c9, t 11-CLA-PTX （P〈0.01）. Compared with untreated cells, the tl0, c12-CLA-PTX and c9, tl 1-CLA-PTX arrested cell cycle progression at the S and G2-M phase. The amount of cellular uptake of t 10, c 12-CLA-PTX was significantly higher than that of CLA-mixture-PTX （P〈0.01）, which was significantly higher than that of c9, t1 1-CLA-PTX （P〈0.01）. The rank of in vivo anti-tumor activity was tl0, c12-CLA-PTX〉CLA-mixture-PTX〉 c9, t1 1-CLA-PTX （P〈0.01）. In conclusion, our study demonstrated that both tl0, cl2-CLA-PTX and c9, tl 1-CLA-PTX has significant anti-tumor activity in MCF-7 cell line. And while c9, tl 1-CLA-PTX showed weaker inhibitory effect than CLA-mixture-PTX, stronger inhibitory effect was presented by t10, c12-CLA-PTX, which could be a promising alternative for CLA-mixture-PTX.展开更多
目的探讨血清正五聚蛋白3(PTX-3)、补体Clq肿瘤坏死因子相关蛋白9(CTRP9)、巨噬细胞迁移抑制因子(MIF)水平与缺血性脑卒中患者神经功能及短期预后的关系.方法选取本院2017年7月至2018年7月收治的缺血性脑卒中患者180例作为研究对象,根...目的探讨血清正五聚蛋白3(PTX-3)、补体Clq肿瘤坏死因子相关蛋白9(CTRP9)、巨噬细胞迁移抑制因子(MIF)水平与缺血性脑卒中患者神经功能及短期预后的关系.方法选取本院2017年7月至2018年7月收治的缺血性脑卒中患者180例作为研究对象,根据神经功能缺损情况分为重度(n=56)、中度(n=76)、轻度(n=48).比较不同神经功能缺损程度及不同预后患者血清PTX-3、CTRP9、MIF水平、美国国立卫生研究院卒中量表(NIHSS)评分,分析血清PTX-3、CTRP9、MIF与NI-HSS、生活能力评分(mRs)评分的相关性,受试者工作特征(ROC)曲线及ROC曲线下面积(AUC)分析各血清指标对短期预后的预测价值.结果血清PTX-3、MIF与NIHSS、mRs评分呈正相关,CTRP9水平与NIHSS、mRs评分呈负相关(P<0.05);预测短期预后的AUC:治疗5 d PTX-3>治疗5 d MIF>治疗5 d CTRP9>治疗3 d MIF>治疗3 d CTRP9>治疗3 d PTX-3,差异有统计学意义(P<0.05);治疗5 d血清PTX-3、CTRP9、MIF联合预测短期预后的AUC为0.915,大于治疗3 d的0.887(P<0.05).结论血清PTX-3、MIF与缺血性脑卒中患者神经功能、短期预后呈正相关,CTRP9水平与神经功能、短期预后呈负相关,三者联合能可靠预测患者短期预后.展开更多
基金National Natural Science Foundation of China (Grant No.81172992)the National Basic Research Program of China (973 Program,Grant No.2013CB932501)Innovation Team of Ministry of Education (Grant No.BMU20110263)
文摘Considering the results of our previous research that conjugated linoleic acid mixture-paclitaxel （CLA-mixture-PTX） possesses anti-tumor activity against melanoma and brain glioma, the purpose of this study was to investigate the potential anti-tumor efficacy of cis-9, trans- 1 1-conjugated linoleic acid-paclitaxel （c9, tl 1-CLA-PTX） and trans- 1 O, cis- 12-conjugated linoleic acid-paclitaxel （tl0, c12-CLA-PTX） on MCF-7 breast cancer cell line in vitro and in vivo. The in vitro cytotoxicity, apoptosis induction effect and cell cycle arresting effect of c9, t1 1-CLA-PTX and t10, c12-CLA-PTX were investigated. The in vitro cellular uptake of c9, tl 1-CLA-PTX and tl0, cl2-CLA-PTX in MCF-7 cells were also analyzed. Besides, the anti-tumor activity of c9, tl 1-CLA-PTX and tl0, cl2-CLA-PTX was evaluated in MCF-7 tumor bearing nude mice in vivo. The in vitro cytotoxicity results showed that the value of ICs0 of the tl 0, c l2-CLA-PTX is （0.17±0.02） μM, compared with that of （1.08±0.15） μM in CLA-mixture-PTX and （6.50±1.20） μM in c9, tl 1-CLA-PTX treatment group （P〈0.01）. Both tl0, cl2-CLA-PTX and c9, t l 1-CLA-PTX increased the percentage of total apoptotic cells compared with that of control （P〈0.01）. And the rank of apoptosis induction efficacy was t 10, c 12-CLA-PTX〉CLA-mixture-PTX〉c9, t 11-CLA-PTX （P〈0.01）. Compared with untreated cells, the tl0, c12-CLA-PTX and c9, tl 1-CLA-PTX arrested cell cycle progression at the S and G2-M phase. The amount of cellular uptake of t 10, c 12-CLA-PTX was significantly higher than that of CLA-mixture-PTX （P〈0.01）, which was significantly higher than that of c9, t1 1-CLA-PTX （P〈0.01）. The rank of in vivo anti-tumor activity was tl0, c12-CLA-PTX〉CLA-mixture-PTX〉 c9, t1 1-CLA-PTX （P〈0.01）. In conclusion, our study demonstrated that both tl0, cl2-CLA-PTX and c9, tl 1-CLA-PTX has significant anti-tumor activity in MCF-7 cell line. And while c9, tl 1-CLA-PTX showed weaker inhibitory effect than CLA-mixture-PTX, stronger inhibitory effect was presented by t10, c12-CLA-PTX, which could be a promising alternative for CLA-mixture-PTX.
文摘目的探讨血清正五聚蛋白3(PTX-3)、补体Clq肿瘤坏死因子相关蛋白9(CTRP9)、巨噬细胞迁移抑制因子(MIF)水平与缺血性脑卒中患者神经功能及短期预后的关系.方法选取本院2017年7月至2018年7月收治的缺血性脑卒中患者180例作为研究对象,根据神经功能缺损情况分为重度(n=56)、中度(n=76)、轻度(n=48).比较不同神经功能缺损程度及不同预后患者血清PTX-3、CTRP9、MIF水平、美国国立卫生研究院卒中量表(NIHSS)评分,分析血清PTX-3、CTRP9、MIF与NI-HSS、生活能力评分(mRs)评分的相关性,受试者工作特征(ROC)曲线及ROC曲线下面积(AUC)分析各血清指标对短期预后的预测价值.结果血清PTX-3、MIF与NIHSS、mRs评分呈正相关,CTRP9水平与NIHSS、mRs评分呈负相关(P<0.05);预测短期预后的AUC:治疗5 d PTX-3>治疗5 d MIF>治疗5 d CTRP9>治疗3 d MIF>治疗3 d CTRP9>治疗3 d PTX-3,差异有统计学意义(P<0.05);治疗5 d血清PTX-3、CTRP9、MIF联合预测短期预后的AUC为0.915,大于治疗3 d的0.887(P<0.05).结论血清PTX-3、MIF与缺血性脑卒中患者神经功能、短期预后呈正相关,CTRP9水平与神经功能、短期预后呈负相关,三者联合能可靠预测患者短期预后.
